Kimialys
Tristan Garde currently serves as Co-Lead Investor and Board Member at Dealt, where the focus is on enhancing retailers' offers with personalized services. Tristan also holds the position of Investment Associate at GO CAPITAL, a prominent seed and venture capital firm in France that supports responsible innovation across multiple sectors. Additional roles include Lead Investor and Board Member at Kimialys and Sport Quantum, both of which specialize in innovative diagnostic tests and sports performance measurement, respectively. Tristan is also a Board Member at Teamstarter, a company centered on employee engagement through a SaaS crowdfunding platform. Previous experience includes serving as a Senior Financial Advisor at Eurasanté and multiple positions at 5M Ventures, where responsibilities ranged from startup sourcing to deal flow management. Educational credentials include a Graduate Program in Corporate Finance from Audencia and an MBA from the Beijing Institute of Technology.
This person is not in the org chart
This person is not in any teams
Kimialys
We are a team of chemists and biosensor engineers gathered around a common mission: shaping the future of biodetection for a better world. Kimialys is the result of 10 years of meticulous academic research in surface chemistry. Controlling what is happening on the surface is a fundamental aspect of biosensing techniques such as rapid tests, point-of-care diagnostics, and real-time sensors. Without the right surface interactions, even the most advanced biosensors can falter, leading to misleading results. Our research efforts have always been to optimize these crucial parameters, ensuring both precision and reliable biodetection. Founded in 2020, Kimialys is leading the charge in harnessing surface chemistry to revolutionize diagnostics and drug development, all supported by our patented K-One® technology. Building on this foundation, our coated gold nanoparticles elevate rapid diagnostic tests in terms of sensitivity, specificity and reproducibility. Additionally, our expertise in sensor chip functionalisation combined with our expertise in Surface Plasmon Resonance analysis empowers us to detect, screen, and select the most suitable biologics for both diagnostic and therapeutic applications. Reliability, robustness, and adaptability are not just benefits of our technology; they are the cornerstones of the relationships we build. For every customer we collaborate with, thousands of patients stand to benefit from our work.